AN2 Therapeutics (ANTX) Cash from Operations (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Cash from Operations of 12073000.0 for Q1 2026, down 13.9% year-over-year from 14021452.83 in Q1 2025, and down 130.58% quarter-over-quarter from 5236000.0 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Cash from Operations (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Cash from Operations for 6 consecutive years, with 12073000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 13.9% year-over-year to 12073000.0; the TTM figure through Mar 2026 stood at 31307000.0 (up 25.91% YoY), while the FY2025 annual figure was 29834000.0, up 39.43% from the prior year.
- Cash from Operations declined to 12073000.0 in Q1 2026 per ANTX's latest filing, from 5236000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5236000.0 in Q4 2025 and bottomed at 17600000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 10465529.41 across 5 years, with a median of 10600000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 336.94% — and 2024, when it surged 69.24%.
- AN2 Therapeutics' Cash from Operations stood at 7638000.0 in 2022, then plunged by 123.72% to 17088000.0 in 2023, then soared by 69.24% to 5257000.0 in 2024, then gained by 0.4% to 5236000.0 in 2025, then sank by 130.58% to 12073000.0 in 2026.
- Business Quant data shows ANTX's Cash from Operations at 12073000.0 in Q1 2026, 5236000.0 in Q4 2025, and 6375000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | -7.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.00 Mn |
| Mar 31, 2026 | -12.10 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -6.38 Mn |
| Jun 30, 2025 | -7.60 Mn |
| Mar 31, 2025 | -10.62 Mn |
| Dec 31, 2024 | -5.26 Mn |
| Sep 30, 2024 | -12.00 Mn |
| Jun 30, 2024 | -14.40 Mn |
| Mar 31, 2024 | -17.60 Mn |
| Dec 31, 2023 | -17.07 Mn |
| Sep 30, 2023 | -11.80 Mn |
| Jun 30, 2023 | -12.82 Mn |
| Mar 31, 2023 | -11.60 Mn |
| Dec 31, 2022 | -7.64 Mn |
| Sep 30, 2022 | -9.49 Mn |
| Jun 30, 2022 | -9.60 Mn |
| Mar 31, 2022 | -6.74 Mn |
| Dec 31, 2021 | -8.99 Mn |
| Sep 30, 2021 | -4.69 Mn |